What Happened? ToolGen’s Convertible Bond Exercise
On September 18, 2025, ToolGen announced the exercise of convertible bonds for 92,840 shares. The conversion price is 29,620 KRW, and the new shares are scheduled to be listed on September 29 and October 13. This represents 1.08% of the company’s market capitalization.
Why Does This Matter?
The exercise of convertible bonds leads to an increase in the number of outstanding shares, raising the possibility of stock dilution. The significant gap between the current stock price (7 KRW) and the conversion price (29,620 KRW) can create unease among investors. Additionally, the increase in circulating supply can amplify stock price volatility.
ToolGen’s Current State and Future Outlook
- Declining Revenue and Structural Changes: Based on the 2025 semi-annual report, ToolGen experienced a decline in revenue from its patent monetization business and a sharp drop in license income. The increase in other revenue streams is a positive sign.
- R&D Investment: High R&D investment relative to revenue is positive but contributes to short-term profitability challenges.
- Financial Status: Negative operating cash flow and continued net loss. Convertible bond issuance adds to financial burden.
- Intellectual Property: A rich portfolio of intellectual property, including CRISPR gene editing technology, offers long-term growth potential.
What Should Investors Do?
While the immediate risk of stock dilution is limited, the existence of convertible bonds can weigh on market sentiment. ToolGen investors should consider the following:
- Recovery of the patent monetization business and growth of new business areas.
- Progress in pipeline development and the potential for successful commercialization.
- Securing financial soundness and improving R&D investment efficiency.
- Adapting to changes in the macroeconomic environment.
Careful monitoring of ToolGen’s fundamentals and stock price movements is crucial before making investment decisions.